Literature DB >> 14724440

Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C.

Victor I Machicao1, Hugo Bonatti, Murli Krishna, Bashar A Aqel, Frank J Lukens, Justin H Nguyen, Barry G Rosser, Raj Satyanarayana, Hani P Grewal, Winston R Hewitt, Denise M Harnois, Julia E Crook, Jeffery L Steers, Rolland C Dickson.   

Abstract

BACKGROUND: The use of liver allografts from an older donor (OD) (age>50 years) is a widespread strategy to manage the disparity between supply and demand of organs for liver transplantation. This study determines the effect of OD allografts on fibrosis progression and graft survival after liver transplantation in patients with and without infection caused by hepatitis C virus (HCV).
METHODS: All patients undergoing liver transplantation at our center from March 1998 to December 2001 were analyzed. Protocol liver biopsies were performed at 1, 16, and 52 weeks after transplantation and yearly thereafter. One liver pathologist scored all biopsy specimens for modified hepatic activity index (0-18) and fibrosis (0-6).
RESULTS: A total of 402 patients (167 with HCV and 235 without HCV) underwent liver transplantation during the study period. Among patients with HCV, baseline characteristics of OD recipients were similar to younger donor (YD) (age<50 years) recipients. In patients with HCV, graft survival was shorter in OD graft recipients than in YD recipients (P<0.001). In patients without HCV, graft survival was independent of donor age. In patients with HCV, a fibrosis score of 3 or greater was present in 17% of OD recipients at 4 months and in 26% at 12 months after transplantation, compared with 8% of YD recipients at 4 months and 13% at 12 months (P<0.001).
CONCLUSIONS: Liver transplantation with OD grafts is associated with rapid progression of fibrosis and decreased graft survival in patients with HCV, but not in patients without HCV. OD grafts should be considered preferentially for patients without HCV.

Entities:  

Mesh:

Year:  2004        PMID: 14724440     DOI: 10.1097/01.TP.0000095896.07048.BB

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  25 in total

1.  Elderly recipients of hepatitis C positive renal allografts can quickly develop liver disease.

Authors:  Tanya R Flohr; Hugo Bonatti; Tjasa Hranjec; Doug S Keith; Peter I Lobo; Sean C Kumer; Timothy M Schmitt; Robert G Sawyer; Timothy L Pruett; John P Roberts; Kenneth L Brayman
Journal:  J Surg Res       Date:  2011-11-19       Impact factor: 2.192

Review 2.  How important is donor age in liver transplantation?

Authors:  Alberto Lué; Estela Solanas; Pedro Baptista; Sara Lorente; Juan J Araiz; Agustin Garcia-Gil; M Trinidad Serrano
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

3.  Excess body weight, liver steatosis, and early fibrosis progression due to hepatitis C recurrence after liver transplantation.

Authors:  Pierluigi Toniutto; Carlo Fabris; Claudio Avellini; Rosalba Minisini; Davide Bitetto; Elisabetta Rossi; Carlo Smirne; Mario Pirisi
Journal:  World J Gastroenterol       Date:  2005-10-14       Impact factor: 5.742

4.  Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation.

Authors:  Robert J Fontana; Eric A Hughes; Henry Appelman; Robert Hindes; Dessislava Dimitrova; Marc Bifano
Journal:  Liver Transpl       Date:  2012-09       Impact factor: 5.799

5.  Strategies to reduce hepatitis C virus recurrence after liver transplantation.

Authors:  Ruben Ciria; María Pleguezuelo; Shirin Elizabeth Khorsandi; Diego Davila; Abid Suddle; Hector Vilca-Melendez; Sebastian Rufian; Manuel de la Mata; Javier Briceño; Pedro López Cillero; Nigel Heaton
Journal:  World J Hepatol       Date:  2013-05-27

6.  Association of age-dependent liver injury and fibrosis with immune cell populations.

Authors:  Bradley H Collins; Zoie E Holzknecht; Kellie A Lynn; Gregory D Sempowski; Catherine C Smith; Songling Liu; William Parker; Don C Rockey
Journal:  Liver Int       Date:  2013-05-26       Impact factor: 5.828

7.  Restricting liver transplant recipients to younger donors does not increase the wait-list time or the dropout rate: the hepatitis C experience.

Authors:  Jennifer A Flemming; Parsia A Vagefi; Chris E Freise; Francis Y Yao; Norah A Terrault
Journal:  Liver Transpl       Date:  2014-09-03       Impact factor: 5.799

8.  Donor Factors Including Donor Risk Index Predict Fibrosis Progression, Allograft Loss, and Patient Survival following Liver Transplantation for Hepatitis C Virus.

Authors:  Arun Jesudian; Sameer Desale; Jonathan Julia; Elizabeth Landry; Christopher Maxwell; Bhaskar Kallakury; Jacqueline Laurin; Kirti Shetty
Journal:  J Clin Exp Hepatol       Date:  2015-11-12

9.  Prevention of hepatitis C recurrence after liver transplantation: An update.

Authors:  Marco Carbone; Ilaria Lenci; Leonardo Baiocchi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-08-06

10.  Long-term results using old liver grafts for transplantation: sexagenerian versus liver donors older than 70 years.

Authors:  Carlos Jiménez-Romero; Marta Clemares-Lama; Alejandro Manrique-Municio; Alvaro García-Sesma; Jorge Calvo-Pulido; Enrique Moreno-González
Journal:  World J Surg       Date:  2013-09       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.